drugset / Trial / NCT06294912

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

NCT06294912

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.

Timeline

Start
2024-04-18
Primary completion
2025-01-06
Completion
2025-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-7602 Unknown Oral
Background Artemether Small molecule Oral
Background Artesunate Small molecule Intravenous
Background Atovaquone Small molecule Oral
Background Primaquine Small molecule Oral
Background Proguanil Small molecule Oral
Background lumefantrine Small molecule Oral

Indications